Research Analysts Set Expectations for Curis FY2025 Earnings

Curis, Inc. (NASDAQ:CRIS) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings estimates for Curis in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek anticipates that the biotechnology company will earn ($2.34) per share for the year. The consensus estimate for Curis’ current full-year earnings is ($7.12) per share.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Curis in a research note on Tuesday, December 10th.

Curis Trading Down 0.3 %

Shares of NASDAQ:CRIS opened at $3.42 on Thursday. Curis has a 12 month low of $2.86 and a 12 month high of $17.49. The company has a market capitalization of $28.97 million, a price-to-earnings ratio of -0.44 and a beta of 3.42. The firm’s 50-day moving average is $3.61 and its 200 day moving average is $4.71.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Curis stock. Point72 Asset Management L.P. lifted its stake in shares of Curis, Inc. (NASDAQ:CRIS) by 795.5% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 108,356 shares of the biotechnology company’s stock after acquiring an additional 96,256 shares during the quarter. Point72 Asset Management L.P. owned approximately 1.84% of Curis worth $748,000 at the end of the most recent reporting period. Institutional investors own 29.97% of the company’s stock.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.